ClinicalTrials.gg
CompletedNCT01019356Updated Jan 20, 2022

Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome

An interventional study of Rosiglitazone and Acarbose in Polycystic Ovary Syndrome, sponsored by Jean-Patrice Baillargeon. Completed at 1 site in Canada. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-20.

Sponsored by Jean-Patrice Baillargeon · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies in Polycystic Ovary Syndrome with a site in Canada — 3 open to participants now, 4 under way, none of them phase 3. Polycystic Ovary Syndrome · Canada.

Enrollment
6th of 12
52 · median 52
Started
2006
the only one that year
No phase
9 of 16
2 open now
Registered
2nd of 16
by date
Lead sponsor
1 of 16
Jean-Patrice Baillargeon

Among the 16 studies in Polycystic Ovary Syndrome with a site in Canada, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2006, is one of 9 with no phase, and was the 2nd registered.

Polycystic Ovary Syndrome

958 studies on the registry are indexed under Polycystic Ovary Syndrome; 175 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

3 of the 16 studies in Polycystic Ovary Syndrome with a site in Canada are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Polycystic Ovary Syndrome with a site in Canada, or all of them as a file.
02

Study summary

The investigators hypothesis is that free fatty acids (FFA) accumulation in non fatty tissues would lead to insulin resistance and hyperandrogenism in PCOS women. Accordingly, Peroxisome Proliferator-Activated Receptor gamma (PPARγ) agonist (rosiglitazone) would be a great therapeutic option for PCOS as their activation induces transcription factors of gene implicated in fatty acids metabolism.

The aim is to verify if insulin-related hyperandrogenism can be reversed in women having polycystic ovary syndrome following an 8-week treatment with rosiglitazone compared to simple insulin reduction with acarbose.

For the purpose of this study, 14 lean women (BMI ≤ 25 kg/m2) and 36 obese women (BMI 30-39 kg/m2) with PCOS as well as 14 lean and 14 obese control women will be recruited to determine their insulin sensibility (insulin levels, M-value, metabolic clearance rate of glucose)and FFA metabolism (FFA levels, rythm of apparition and disapearance of FFA) during a 75g oral glucose tolerance test and a 2-step insulin-glucose clamp.

Read the detailed description

Polycystic ovary syndrome (PCOS) is a very common but complex endocrine disorder affecting 6 to 10% of childbearing age women. To diagnose PCOS, women must display two of these three symptoms: clinical or biochemical hyperandrogenism, oligoamenorrhea, and/or echographycally confirmed polycystic ovary. Many studies have also demonstrated that PCOS women are more insulin resistant than control women when matched for body mass index (BMI). Thus, insulin resistance (IR) and secondary hyperinsulinemia would be important premises in the development of PCOS. In fact, the prevalence of type 2 diabetes (T2D) is tripled in PCOS women.

Higher free fatty acid (FFA) concentrations were also observed in the circulation of PCOS women. As FFA accumulates in liver and muscle instead of fat cells, this could be an important cause of IR according to the theory of lipotoxicity. Some indirect evidences are suggesting that FFA accumulation in androgen secreting cells (ovary and adrenal gland) could enhance their androgen production. Based on these findings, our hypothesis is that FFA accumulation in non fatty tissues would lead to IR and hyperandrogenism in PCOS women. Accordingly, Peroxisome Proliferator-Activated Receptor gamma (PPARγ) agonist (rosiglitazone) would be a great therapeutic option for PCOS as their activation induces transcription factors of gene implicated in fatty acids metabolism.

The aim is to verify if insulin-related hyperandrogenism can be reversed in PCOS women following an 8-week treatment with rosiglitazone compared to simple insulin reduction with acarbose. For the purpose of this study, 14 lean women (BMI ≤ 25 kg/m2) and 36 obese women (BMI 30-39 kg/m2) with PCOS as well as 14 lean and 14 obese control women will be recruited to determine their insulin sensibility (insulin levels, M-value, metabolic clearance rate of glucose)and FFA metabolism (FFA levels, rythm of apparition and disapearance of FFA) during a 75g oral glucose tolerance test and a 2-step insulin-glucose clamp.

03

Conditions studied

  • Polycystic Ovary Syndrome

Keywords

  • PCOS
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

PCOS :

  • Biochemical hyperandrogenism (free testosterone ≥ 50 pmol/l)
  • Oligomenorhea (≤ 8 menstrual cycle per year)

Health volunteers :

  • Normal menstrual cycle
  • Normal levels of free and total testosterone
  • No family history with PCOS

Exclusion criteria

Exclusion Criteria:

  • Diabetes or glucose intolerance
  • Current or past use within 3 months of oral
  • Current or past use within 3 months of medications known to affect insulin sensitivity (metformin, PPARy agonists, b-blockers, thiazides, calcium channel blockers, , etc.)
  • Pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious or neoplastic disease (other than non-melanoma skin cancer)
  • Documented or suspected recent (within one year) history of drug abuse or alcoholism
  • Use of any drug within three months prior to study onset

Healthy volunteers :

  • History of gestational diabetes
  • Positive family history for first-degree relative with diabetes
  • Disorders linked to insulin resistance (hypertension, dyslipidemia or acanthosis nigricans)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Rosiglitazone

    Lean and obese PCOS women

    Drug: Rosiglitazone

  • Active comparator
    Acarbose

    Obese PCOS women

    Drug: Acarbose

  • No intervention
    Control

    Obese and lean healthy women evaluated only at baseline

Interventions

  • 4 mg twice daily for 8 weeks orally

    Also known as: Avandia

  • 100 mg three times daily for 8 weeks orally

    Also known as: Prandase

06

What researchers measure

Primary outcomes

  1. Androgen hyper-responsiveness to insulin - Ratio

    The calculated ratio of free testosterone to the area under the insulin curve during an OGTT

    Time frame: 8 weeks

Secondary outcomes

  1. Androgen hyper-responsiveness to insulin - Relationship

    Determined by the relationship between testosterone and insulin levels during an OGTT.

    Time frame: 8 weeks

  2. Insulin sensitivity

    Determined by a 2-step insulin-glucose clamp

    Time frame: 8 weeks

  3. Insulin secretion

    Determined by a 2-step insulin-glucose clamp

    Time frame: 8 weeks

  4. Hepatic glucose production

    Determined by a 2-step insulin-glucose clamp

    Time frame: 8 weeks

  5. Plasma DCI-IPG during euglycemic-hyperinsulinemic clamp

    Measured during steady-state

    Time frame: 8 weeks

07

Study locations

1 site
  • Université de Sherbrooke
    Sherbrooke, Quebec J1H 5N4, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Jul 2021 and a completion of Jul 2021. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2009
First posted
Nov 25, 2009
Start
Aug 2006
Primary completionActual
Jul 2021
CompletionActual
Jul 2021
Last update
Jan 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01019356
Lead sponsor
Jean-Patrice Baillargeon
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Jean-Patrice Baillargeon (MD, Université de Sherbrooke) — Sponsor-investigator
First posted
Nov 25, 2009
Start date
Aug 2006
Primary completion
Jul 2021
Completion
Jul 2021
Last update
Jan 20, 2022

Study contacts

Jean-Patrice Baillargeon, MD, MSc
principal investigator · Université de Sherbrooke

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosiglitazone

Start the discussion